00009276538-K2026-03-06false00009276532026-03-062026-03-060000927653us-gaap:CommonStockMember2026-03-062026-03-060000927653mck:A1.625NotesDue2026Member2026-03-062026-03-060000927653mck:A3.125NotesDue2029Member2026-03-062026-03-06

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 6, 2026
mckessonlogoa04.jpg
McKESSON CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware1-1325294-3207296
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
6555 State Hwy 161
Irving, TX 75039
(Address of Principal Executive Offices, and Zip Code)
(972) 446-4800
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common stock, $0.01 par valueMCKNew York Stock Exchange
1.625% Notes due 2026MCK26New York Stock Exchange
3.125% Notes due 2029MCK29New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 7.01 Regulation FD Disclosure
On March 6, 2026, the company issued the news release attached to this report as Exhibit 99.1.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.  Description
99.1 
104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 6, 2026
 
McKesson Corporation
By:/s/ Britt J. Vitalone
 
Britt J. Vitalone
 
Executive Vice President and
 
Chief Financial Officer


Exhibit 99.1
mckessonlogoa03.jpg

MCKESSON CORPORATION ANNOUNCES FOURTH QUARTER FISCAL 2026 EARNINGS RELEASE DATE AND PARTICIPATION IN UPCOMING CONFERENCES

IRVING, Texas, March 6, 2026 -- McKesson Corporation (NYSE: MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026.

McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on February 4, 2026.

The live webcast for each event will be available on McKesson’s Investor Relations website.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

Contacts

Investors
Investors@McKesson.com